TABLE 1.

Associations between GGH expression level and clinicopathological features of UCEC.

Characteristics	GGH expression		P
	Low (n = 272)	High (n = 271)
Clinical stage (%)
Stage I	190 (69.9%)	149 (55.0%)	0.003 a
Stage II	17 (6.2%)	34 (12.5%)
Stage III	53 (19.5%)	71 (26.2%)
Stage IV	12 (4.4%)	17 (6.3%)
Histologic grade (%)
G1	71 (26.8%)	27 (10.1%)	<0.001 a
G2	72 (27.2%)	48 (18.0%)
G3	122 (46.0%)	192 (71.9%)
Residual tumor (%)
R0	192 (91.9%)	180 (89.6%)	0.54
R1	11 (5.3%)	11 (5.5%)
R2	6 (2.9%)	10 (5.0%)
Primary therapy outcome (%)
CR	236 (94.0%)	200 (89.7%)	0.035 a , b
PD	6 (2.4%)	14 (6.3%)
PR	4 (1.6%)	8 (3.6%)
SD	5 (2.0%)	1 (0.4%)
Histological type (%)
Endometrioid	216 (79.4%)	191 (70.5%)	0.056
Mixed	9 (3.3%)	13 (4.8%)
Serous	47 (17.3%)	67 (24.7%)
Diabetes (%)
No	163 (72.8%)	158 (72.5%)	1
Yes	61 (27.2%)	60 (27.5%)
Menopause status (%)
Peri	11 (4.5%)	6 (2.4%)	0.435
Post	218 (88.3%)	227 (90.8%)
Pre	18 (7.3%)	17 (6.8%)
Race (%)
Asian	11 (4.4%)	9 (3.6%)	0.028 a
Black or African American	41 (16.4%)	65 (26.2%)
White	198 (79.2%)	174 (70.2%)
Surgical approach (%)
Minimally Invasive	85 (32.1%)	116 (45.3%)	0.003 a
open	180 (67.9%)	140 (54.7%)
Hormones therapy (%)
No	150 (86.7%)	144 (86.7%)	1
Yes	23 (13.3%)	22 (13.3%)
Radiation therapy (%)
No	141 (53.6%)	133 (52.2%)	0.807
Yes	122 (46.4%)	122 (47.8%)
TP53 status (%)
Mutant	77 (28.9%)	112 (43.1%)	0.001 a
Wild-type	189 (71.1%)	148 (56.9%)
Age [median (IQR)]	63.00 [56.00, 71.00]	64.00 [57.00,72.00]	0.114 c
Height [median (IQR)]	161.00 [158.00, 166.00]	161.00 [156.00,166.00]	0.273 c
Weight [median (IQR)]	88.00 [72.00, 107.00]	79.00 [64.00,99.75]	0.001 a , c
BMI [median (IQR)]	33.75 [27.78, 39.79]	30.86 [25.48,37.98]	0.003 a , c
Tumor invasion (%) [median (IQR)]	36.00 [12.00, 57.50]	49.00 [18.50,67.00]	0.041 a , c

^aStatistically significant.

^bFisher exact test.

^cWilcoxon rank sum test.